Prilenia Therapeutics and Ferrer have begun the confirmatory Phase III PRECISE-HD clinical trial assessing pridopidine as a ...
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of ...
Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeksMean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacyUp to 84 ...
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus ...
Hamas says it will hand Gaza’s government to a technocratic committee, but questions remain over disarmament and Israel’s ...
Tregzi (clinically known as Orca-T) is an allogeneic cellular immunotherapy consisting of purified regulatory and conventional T cells.
With the completion of the Muscatine Marina Confined Disposal Facility (CDF) Relocation Project, the City of Muscatine has ...
Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs.
In many cases, no one has actually been tasked with designing the control logic, the sequence of operations, and the comms ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...
Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results